Core Viewpoint - Rosen Law Firm is reminding investors who purchased agilon health, inc. securities between February 26, 2025, and August 4, 2025, about the March 2, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought agilon securities during the specified Class Period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The deadline to move the Court to serve as lead plaintiff is March 2, 2026, with the lead plaintiff representing other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that defendants made false or misleading statements and failed to disclose critical information, including: 1. Reckless guidance for 2025 that was unlikely to be achieved due to known industry challenges [5]. 2. Material overstatement of the financial impact from strategic actions taken by agilon to mitigate risk [5]. 3. Overall misleading statements regarding agilon's business operations and prospects throughout the Class Period [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting their own achievements, including the largest securities class action settlement against a Chinese company [4]. - The firm has consistently ranked highly in securities class action settlements, recovering hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4].

NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of agilon health, inc. (NYSE: AGL) between February 26, 2025 and August 4, 2025, both dates inclusive (the “Class Period”), of the important March 2, 2026 lead plaintiff deadline in the securities class action first filed by the Firm. SO WHAT: If you purchased agilon securities during the Class Period you may be entitled to compensation without payment of any out of pocket fe ...

Deadline Soon: agilon health, inc. (AGL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitFeb 27, 2026 12:00 PM Eastern Standard Time# Deadline Soon: agilon health, inc. (AGL) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud LawsuitShare---LOS ANGELES--([BUSINESS WIRE])-- [The Law Offices of Frank R. Cruz] reminds investors of the upcoming March 2, 2026 deadline to participate as a lead plaintiff i ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against agilon health, inc. due to alleged violations of federal securities laws, with a deadline for investors to seek lead plaintiff status in a class action lawsuit by March 2, 2026 [4][6]. Group 1: Allegations Against Agilon Health - The complaint alleges that agilon health and its executives made false and misleading statements regarding the company's financial guidance for 2025, which they knew was unattainable due to industry challenges [6]. - It is claimed that the company overstated the financial benefits from strategic actions taken to mitigate risks, leading to materially false representations about its business and prospects [6]. - Following the release of disappointing second-quarter results on August 4, 2025, agilon health's stock plummeted by 51.5% the next day, reflecting the market's reaction to the disclosed information [7]. Group 2: Legal Proceedings and Investor Actions - Investors who purchased agilon health securities between February 26, 2025, and August 4, 2025, are encouraged to contact Faruqi & Faruqi to discuss their legal rights and options [1][9]. - The role of lead plaintiff in the class action is designated to the investor with the largest financial interest, who will oversee the litigation on behalf of the class [8]. - The firm is also seeking information from whistleblowers, former employees, and shareholders regarding agilon health's conduct to support the investigation [9].

Performance in 2025 was impacted by elevated medical cost trends, specifically a step-up in inpatient volume and several discrete multimillion-dollar claims in the third quarter. Management is executing a strategic pivot that prioritizes economic sustainability over membership growth, leading to the intentional exit of unprofitable payer contracts. The company is migrating certain markets to care coordination fee models to reduce downside risk while maintaining a long-term path to full-risk arrangemen ...

Williams also addressed CMS’s Medicare Advantage (MA) Advance Notice for 2027, saying the proposal “does not sufficiently reflect” rising costs and utilization from chronic disease and an aging Medicare population. He said the company expects the impact of the risk model revision and normalization described in the Advance Notice to be “generally in line with the national average,” and argued that agilon’s burden of illness and clinical pathway programs can help mitigate risk model impacts, as they did durin ...

In addition, given the focus of our model is the assessment of conditions at the point of care with diagnoses tied to documentation from a visit, we believe we have minimal exposure to unlinked or audio-only coding. We believe our ability to differentiate on the management of medical cost and quality outcomes should continue to position us well with health plans and physicians, with the expectation that the rate and cost spread will ultimately normalize over time. Throughout the year, we advanced several ke ...

agilon health (NYSE:AGL) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsCraig Jones - VPEvan Smith - SVP of Investor RelationsJailendra Singh - Managing DirectorJeff Schwaneke - EVP and CFOMatthew Wagner - Managing Director of Healthcare Investment BankingRon Williams - Executive ChairmanConference Call ParticipantsJack Slevin - VP and Equity Research AnalystJustin Lake - AnalystMichael Ha - Senior Research AnalystRyan Langston - Director and Senior Analyst of Healthcare ResearchSte ...

agilon health (NYSE:AGL) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Company ParticipantsCraig Jones - VPEvan Smith - SVP of Investor RelationsJailendra Singh - Managing DirectorJeff Schwaneke - EVP and CFOMatthew Wagner - Managing Director of Healthcare Investment BankingRon Williams - Executive ChairmanConference Call ParticipantsJack Slevin - VP and Equity Research AnalystJustin Lake - AnalystMichael Ha - Senior Research AnalystRyan Langston - Director and Senior Analyst of Healthcare ResearchSte ...

agilon health (NYSE:AGL) Q4 2025 Earnings call February 25, 2026 04:30 PM ET Speaker1Thank you for your patience, everyone. The agilon health fourth quarter 2025 earnings conference call will begin shortly. During the call, you can register to ask questions by pressing star followed by 1 on your telephone keypad. Thank you. Thank you for your patience, everyone. The agilon health fourth quarter 2025 earnings conference call will begin in 1 minute time. In the meantime, you can register to ask questions by p ...